Is Nuo Therapeutics, Inc. (AURX) a Buy, Sell, or Hold?
OTC : AURX
Nuo Therapeutics, Inc.
$0.9 USD
-$0.12 (-11.76%)
- Volume
- 1.5K
- Average Volume
- 2.89K
- Market Capitalization
- $43.57M
- P/E Ratio
- -18.00
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.23
- Year Low
- $0.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.11
Company Overview
OTC
David E. Jorden
Biotechnology
Healthcare
AURX
10
US
USD
Liquidity Metrics
-0.80
1.11
0.93
0.19
0.00
Sales & Valuation
$3.31M
10.55
-31.40
-25.68
-0.04
Profitability
-$0.0531
-$2.51M
-57.72%
-57.72%
266.09%
-122.56%
P/E Metrics
-18.00
-9.10
-9.10
Analyst Price Target & Rating
$3.00
$3.00
$3.00
2/5
0 Analysts
-70.00%
Financial Health Scores
-18.11
3/9
$151K
$1.95M
$3.33M
-$2.22M
Key Metrics (TTM)
$50.22M
12.16
-24.50
1.11
266.09%
-338.42%
-4.84%
-3.44%
42 days
Company Executives
| Name | Title |
|---|---|
| David E. Jorden | Chief Executive Officer, Chief Financial Officer, Secretary & Executive Director |
| Peter Anton Clausen | Chief Operating Officer & Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About Nuo Therapeutics, Inc. (OTC:AURX) Stock
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014. ...
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 17:15:00
HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year's fourth quarter Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter Net operating loss of approximately $446,000 compared to 2025's first quarter net operating loss of approximately $745,000 Operational and Business Update Witnessing robust demand for the Aurix product in private physician office settings Market responding favorably to continued improvement in Medicare related reimbursement for Aurix and a vastly changed overall reimbursement landscape Entered into a Loan and Security Agreement with initial fundings of $1.0 million designed to provide working capital as the company invests in growth and moves closer to breakeven operations “Just over one year ago, Nuo issued our most recent press release and announced the exclusive private label distribution agreement with Smith+Nephew.
Frequently Asked Questions
-
What is the current Nuo Therapeutics, Inc. (AURX) stock price?
-
Nuo Therapeutics, Inc.(OTC:AURX) stock price is $0.9 in the last trading session. During the trading session, AURX stock reached the peak price of $3.23 while $0.8415 was the lowest point it dropped to. The percentage change in AURX stock occurred in the recent session was --11.76% while the dollar amount for the price change in AURX stock was -$0.12.
-
AURX's industry and sector of operation?
-
The OTC listed AURX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AURX?
-
David E. Jorden | Chief Executive Officer, Chief Financial Officer, Secretary & Executive Director
Peter Anton Clausen | Chief Operating Officer & Chief Scientific Officer
|
|
| -
How many employees does AURX have?
-
Number of AURX employees currently stands at 10. AURX operates from 8285 El Rio, Houston, TX 77054, US.
-
Link for AURX official website?
-
Official Website of AURX is: https://www.nuot.com
-
How do I contact AURX?
-
AURX could be contacted at phone #346 396 4770 and can also be accessed through its website. AURX operates from 8285 El Rio, Houston, TX 77054, US.
-
How many shares of AURX are traded daily?
-
The average number of AURX shares traded daily for last 3 months was 2.89K.
-
What is the market cap of AURX currently?
-
The market value of AURX currently stands at $43.57M with its latest stock price at $0.9